FibroGen, Astellas advance FG-4592 to phase 2b development for treatment of ... - News-Medical.net PDF Print
News-Medical.net
"We are pleased to report progress in the clinical development program for FG-4592 for the treatment of anemia in CKD patients on dialysis and not on dialysis," said Thomas B. Neff, FibroGen's chief executive officer. "We continue to see signs of ...
FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.